Favipiravir pharmacokinetics in Thai adults with mild COVID‐19: A sub‐study of interpatient variability and ethnic differences in exposure
Ing‐orn Prasanchaimontri, Weerawat Manosuthi, Henry Pertinez, Andrew Owen, Suvimol Niyomnaitham, Rujipas Sirijatuphat, Lantharita Charoenpong, Tim R Cressey, Katherine Copeland, Phongpan Mokmued, Kulkanya Chokephaibulkit
Pharmacology Research & Perspectives, doi:10.1002/prp2.1233
This sub-study sought to characterize the pharmacokinetics (PK) of favipiravir (FPV) within Thai adults and quantitatively assess differences in exposure to those previously reported in other populations as a basis to understand putative differences in efficacy between studies conducted in different regions. It was nested within a prospective trial of adults with symptomatic COVID-19 infection without pneumonia receiving 1800 mg FPV twice-daily on day 1 and 800 mg twice-daily thereafter. Individual PK profiles were fitted with a one-compartment disposition model (firstorder absorption). Eight adults (seven female) with a median age of 39 years and BMI of 27.9 kg/m 2 were included. Seven adults achieved plasma concentrations above the EC 90 in vitro target (25 mg/L), with minimum-maximum concentrations decreasing with repeat dosing. The mean FPV apparent clearance observed in this study was
S U PP O RTI N G I N FO R M ATI O N Additional supporting information can be found online in the Supporting Information section at the end of this article.
References
Anugulruengkitt, Teeraananchai, Chantasrisawad, Promsena, Jantarabenjakul et al., Clinical outcomes of pediatric COVID-19 in a tertiary care center in Bangkok, Thailand, IJID Reg
Arshad, Pertinez, Box, Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics, Clin Pharmacol Ther
Bergstrand, Hooker, Wallin, Mo, Predictioncorrected visual predictive checks for diagnosing nonlinear mixedeffects models, AAPS J
Chen, Chao, Lai, Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients, J Infect
Chiba, Kiso, Nakajima, Co-administration of favipiravir and the remdesivir metabolite GS-441524 effectively reduces SARS-CoV-2 replication in the lungs of the Syrian hamster model, MBio,
doi:/10.1128/mbio.03044-21Core, R: A Language and Environment for Statistical Computing
Doi, Hibino, Hase, A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19, Antimicrob Agents Chemother,
doi:/10.1128/aac.01897-20Driouich, Cochin, Lingas, Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model, Nat Commun
Du, Chen, Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, Clin Pharmacol Ther,
doi:/10.1002/cpt.1844Ette, Williams, Population pharmacokinetics II: estimation methods, Ann Pharmacother
Furuta, Komeno, Nakamura, Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase, Proc Jpn Acad Ser B Phys Biol Sci,
doi:/10.2183/pjab.93.027Ghasemnejad-Berenji, Pashapour, Favipiravir and COVID-19: a simplified summary, Drug Res
Gowen, Sefing, Westover, Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever, Antivir Res,
doi:/10.1016/j.antiviral.2015.07.003Gulhan, Eryuksel, Idriz Oglu, Pharmacokinetic characterization of favipiravir in patients with COVID-19, Br J Clin Pharmacol,
doi:/10.1111/bcp.15227Hung, Ghula, Aziz, The efficacy and adverse effects of favipiravir on patients with COVID-19: a systematic review and meta-analysis of published clinical trials and observational studies, Int J Infect Dis
Irie, Nakagawa, Fujita, Pharmacokinetics of favipiravir in critically ill patients with COVID-19, Clin Transl Sci,
doi:/10.1111/cts.12827Irie, Nakagawa, Fujita, Population pharmacokinetics of favipiravir in patients with COVID-19, CPT Pharmacometrics Syst Pharmacol,
doi:/10.1002/psp4.12685Ison, Scheetz, Understanding the pharmacokinetics of favipiravir: implications for treatment of influenza and COVID-19, EBioMedicine,
doi:/10.1016/j.ebiom.2020.103204Jeon, Ko, Lee, Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs, Antimicrob Agents Chemother
Kaptein, Jacobs, Langendries, Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity, Proc Natl Acad Sci,
doi:/10.1073/pnas.2014441117Kumari, Rawat, Saha, Pipeline pharmacological therapies in clinical trial for COVID-19 pandemic: a recent update, Curr Pharmacol Rep
Lou, Liu, Yao, Clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in COVID-19 patients: an exploratory randomized, controlled trial, Eur J Pharm Sci,
doi:/10.1016/j.ejps.2020.105631Lowe, Brown, Chowdhury, Favipiravir, lopinavirritonavir, or combination therapy (FLARE): a randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19, PLoS Med,
doi:/10.1371/journal.pmed.1004120Mould, Upton, Basic concepts in population modeling, simulation, and model-based drug development, CPT Pharmacometrics Syst Pharmacol
Mould, Upton, Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods, CPT Pharmacometrics Syst Pharmacol
Nguyen, Guedj, Anglaret, Favipiravir pharmacokinetics in Ebola-infected patients of the JIKI trial reveals concentrations lower than targeted, PLoS Negl Trop Dis
Ozsurekci, Oygar, Gürlevik, Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?, Pediatr Nephrol
Pertinez, Rajoli, Khoo, Owen, Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′triphosphate exposure to support posology for SARS-CoV-2, J Antimicrob Chemother,
doi:/10.1093/jac/dkab135Rattanaumpawan, Jirajariyavej, Lerdlamyong, Palavutitotai, Saiyarin, Real-world effectiveness and optimal dosage of favipiravir for treatment of COVID-19: results from a multicenter observational study in Thailand, Antibiotics
Seneviratne, Abeysuriya, De Mel, De Zoysa, Niloofa, Favipiravir in COVID-19, IJPSAT
Shah, Orton, Grinsztejn, Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care, Lancet Respir Med,
doi:/10.1016/s2213-2600(22)00412-xShannon, Selisko, Le, Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis, Nat Commun
Sirijatuphat, Manosuthi, Niyomnaitham, Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized Control Study
Solaymani-Dodaran, Ghanei, Bagheri, Safety and efficacy of favipiravir in moderate to severe SARS-CoV-2 pneumonia, Int Immunopharmacol
Tuesuwan, Mueannoom, Jamnongtanachot, Basis to aid crisis: favipiravir oral solution for hospital compounding during COVID-19 drug shortage, J Pharm Sci
Tırmıkçıoğlu, Favipiravir exposure and pregnancy outcome of COVID-19 patients, Eur J Obstet Gynecol Reprod Biol
Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res,
doi:/10.1038/s41422-020-0282-0Wang, Zhong, Salam, Phase 2a, open-label, dosemulti-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza, EBioMedicine,
doi:/10.1016/j.ebiom.2020.103125{ 'indexed': { 'date-parts': [[2024, 11, 8]],
'date-time': '2024-11-08T05:26:49Z',
'timestamp': 1731043609044,
'version': '3.28.0'},
'reference-count': 52,
'publisher': 'Wiley',
'issue': '6',
'license': [ { 'start': { 'date-parts': [[2024, 11, 7]],
'date-time': '2024-11-07T00:00:00Z',
'timestamp': 1730937600000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}],
'funder': [ { 'DOI': '10.13039/501100004704',
'name': 'National Research Council of Thailand',
'doi-asserted-by': 'publisher',
'award': ['63‐088'],
'id': [{'id': '10.13039/501100004704', 'id-type': 'DOI', 'asserted-by': 'publisher'}]}],
'content-domain': {'domain': ['bpspubs.onlinelibrary.wiley.com'], 'crossmark-restriction': True},
'published-print': {'date-parts': [[2024, 12]]},
'abstract': '<jats:title>Abstract</jats:title><jats:p>This sub‐study sought to characterize the '
'pharmacokinetics (PK) of favipiravir (FPV) within Thai adults and quantitatively assess '
'differences in exposure to those previously reported in other populations as a basis to '
'understand putative differences in efficacy between studies conducted in different regions. '
'It was nested within a prospective trial of adults with symptomatic COVID‐19 infection '
'without pneumonia receiving 1800\u2009mg FPV twice‐daily on day 1 and 800\u2009mg twice‐daily '
'thereafter. Individual PK profiles were fitted with a one‐compartment disposition model '
'(first‐order absorption). Eight adults (seven female) with a median age of 39\u2009years and '
'BMI of 27.9\u2009kg/m<jats:sup>2</jats:sup> were included. Seven adults achieved plasma '
'concentrations above the EC<jats:sub>90</jats:sub> in\xa0vitro target (25\u2009mg/L), with '
'minimum–maximum concentrations decreasing with repeat dosing. The mean FPV apparent clearance '
'observed in this study was 1.1\u2009L/h (coefficient of variation [CV]: 60%), apparent volume '
'of distribution 20.6\u2009L (CV: 40%), absorption rate constant 6.1\u2009h (CV: 100%), and '
'2.4 daily % change in apparent clearance (CV: 315%). Higher exposures were observed in these '
'Thai adults compared with data from previous studies in Chinese, Japanese, and Turkish '
'populations, respectively. Current FPV doses recommended in Thailand achieved target plasma '
'concentrations with higher exposures than those described previously in other populations. '
'The limited sample size prohibits firm conclusions from being drawn but the presented data '
'warrants confirmation with a view to interrogate the appropriateness of doses used in '
'randomized clinical trials that failed to demonstrate efficacy.</jats:p>',
'DOI': '10.1002/prp2.1233',
'type': 'journal-article',
'created': {'date-parts': [[2024, 11, 7]], 'date-time': '2024-11-07T19:50:01Z', 'timestamp': 1731009001000},
'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Favipiravir pharmacokinetics in Thai adults with mild <scp>COVID</scp>‐19: A sub‐study of '
'interpatient variability and ethnic differences in exposure',
'prefix': '10.1002',
'volume': '12',
'author': [ { 'ORCID': 'http://orcid.org/0009-0008-9873-6142',
'authenticated-orcid': False,
'given': 'Ing‐orn',
'family': 'Prasanchaimontri',
'sequence': 'first',
'affiliation': [ { 'name': 'Bureau of Drug and Narcotic, Department of Medical Sciences '
'Ministry of Public Health Nonthaburi Thailand'}]},
{ 'ORCID': 'http://orcid.org/0000-0003-2583-9390',
'authenticated-orcid': False,
'given': 'Weerawat',
'family': 'Manosuthi',
'sequence': 'additional',
'affiliation': [ { 'name': 'Bamrasnaradura Infectious Diseases Institute, Department of '
'Disease Control Ministry of Public Health Nonthaburi '
'Thailand'}]},
{ 'given': 'Henry',
'family': 'Pertinez',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmacology and Therapeutics, Centre of '
'Excellence in Long‐acting Therapeutics (CELT) University of '
'Liverpool Liverpool UK'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-9819-7651',
'authenticated-orcid': False,
'given': 'Andrew',
'family': 'Owen',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmacology and Therapeutics, Centre of '
'Excellence in Long‐acting Therapeutics (CELT) University of '
'Liverpool Liverpool UK'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-4785-2716',
'authenticated-orcid': False,
'given': 'Suvimol',
'family': 'Niyomnaitham',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Pharmacology, Faculty of Medicine Siriraj Hospital '
'Mahidol University Nakhon Pathom Thailand'},
{ 'name': 'Siriraj Institute of Clinical Research (SICRES) Mahidol '
'University Nakhon Pathom Thailand'}]},
{ 'ORCID': 'http://orcid.org/0000-0003-1486-5550',
'authenticated-orcid': False,
'given': 'Rujipas',
'family': 'Sirijatuphat',
'sequence': 'additional',
'affiliation': [ { 'name': 'Department of Medicine, Faculty of Medicine Siriraj Hospital '
'Mahidol University Nakhon Pathom Thailand'}]},
{ 'ORCID': 'http://orcid.org/0000-0003-3811-0267',
'authenticated-orcid': False,
'given': 'Lantharita',
'family': 'Charoenpong',
'sequence': 'additional',
'affiliation': [ { 'name': 'Bamrasnaradura Infectious Diseases Institute, Department of '
'Disease Control Ministry of Public Health Nonthaburi '
'Thailand'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-8106-0974',
'authenticated-orcid': False,
'given': 'Tim\xa0R.',
'family': 'Cressey',
'sequence': 'additional',
'affiliation': [ { 'name': 'AMS‐PHPT Research Collaboration, Department of Medical '
'Technology, Faculty of Associated Medical Sciences Chiang Mai '
'University Chiang Mai Thailand'},
{ 'name': 'Department of Pharmacology and Therapeutics University of '
'Liverpool Liverpool UK'}]},
{ 'ORCID': 'http://orcid.org/0009-0004-8609-8041',
'authenticated-orcid': False,
'given': 'Katherine',
'family': 'Copeland',
'sequence': 'additional',
'affiliation': [ { 'name': 'Siriraj Institute of Clinical Research (SICRES) Mahidol '
'University Nakhon Pathom Thailand'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-9361-2668',
'authenticated-orcid': False,
'given': 'Phongpan',
'family': 'Mokmued',
'sequence': 'additional',
'affiliation': [ { 'name': 'Medical Life Sciences Institute, Department of Medical Sciences '
'Ministry of Public Health Nonthaburi Thailand'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-0140-4600',
'authenticated-orcid': False,
'given': 'Kulkanya',
'family': 'Chokephaibulkit',
'sequence': 'additional',
'affiliation': [ { 'name': 'Siriraj Institute of Clinical Research (SICRES) Mahidol '
'University Nakhon Pathom Thailand'},
{ 'name': 'Department of Pediatrics, Faculty of Medicine Siriraj Hospital '
'Mahidol University Nakhon Pathom Thailand'}]}],
'member': '311',
'published-online': {'date-parts': [[2024, 11, 7]]},
'reference': [ { 'issue': '2',
'key': 'e_1_2_11_2_1',
'first-page': '143',
'article-title': 'Favipiravir in COVID‐19',
'volume': '19',
'author': 'Seneviratne SL',
'year': '2020',
'journal-title': 'IJPSAT'},
{'key': 'e_1_2_11_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1055/a-1296-7935'},
{'key': 'e_1_2_11_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cpt.1844'},
{'key': 'e_1_2_11_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.2183/pjab.93.027'},
{ 'key': 'e_1_2_11_6_1',
'doi-asserted-by': 'publisher',
'DOI': '10.13040/ijpsr.0975-8232.12(4).1950-57'},
{'key': 'e_1_2_11_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijid.2020.10.069'},
{'key': 'e_1_2_11_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41422-020-0282-0'},
{'key': 'e_1_2_11_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/mbio.03044-21'},
{'key': 'e_1_2_11_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/aac.01897-20'},
{ 'key': 'e_1_2_11_11_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ijid.2022.04.035'},
{'key': 'e_1_2_11_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/cts.12827'},
{ 'key': 'e_1_2_11_13_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ejps.2020.105631'},
{ 'key': 'e_1_2_11_14_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.intimp.2021.107522'},
{ 'issue': '5',
'key': 'e_1_2_11_15_1',
'doi-asserted-by': 'crossref',
'first-page': '186',
'DOI': '10.1016/j.jinf.2020.12.005',
'article-title': 'Clinical efficacy and safety of favipiravir in the treatment of '
'COVID‐19 patients',
'volume': '82',
'author': 'Chen P‐J',
'year': '2021',
'journal-title': 'J Infect'},
{'key': 'e_1_2_11_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/jac/dkab135'},
{ 'key': 'e_1_2_11_17_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1371/journal.pmed.1004120'},
{ 'key': 'e_1_2_11_18_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/s2213-2600(22)00412-x'},
{ 'key': 'e_1_2_11_19_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ejogrb.2021.12.001'},
{ 'key': 'e_1_2_11_20_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ijregi.2021.11.003'},
{ 'key': 'e_1_2_11_21_1',
'unstructured': 'COVID‐19 '
'[Thai].2022.https://covid19.dms.go.th/Content/Select_Landding_page?contentId=178'},
{ 'key': 'e_1_2_11_22_1',
'doi-asserted-by': 'crossref',
'first-page': '610',
'DOI': '10.1016/j.xphs.2022.10.026',
'article-title': 'Basis to aid crisis: favipiravir oral solution for hospital compounding '
'during COVID‐19 drug shortage',
'volume': '112',
'author': 'Tuesuwan B',
'year': '2022',
'journal-title': 'J Pharm Sci'},
{ 'key': 'e_1_2_11_23_1',
'unstructured': 'United States Food and Drug Administration.Know Your Treatment Options '
'for '
'COVID‐19.https://www.fda.gov/consumers/consumer‐updates/know‐your‐treatment‐options‐covid‐19'},
{ 'key': 'e_1_2_11_24_1',
'volume-title': 'Coronavirus (COVID‐19) | Drugs',
'author': 'United States Food and Drug Administration',
'year': '2023'},
{ 'key': 'e_1_2_11_25_1',
'volume-title': 'COVID‐19 Treatments and Medications',
'author': 'Centers for Disease Control and Prevention',
'year': '2024'},
{ 'key': 'e_1_2_11_26_1',
'volume-title': 'Coronavirus Disease 2019 (COVID‐19) Treatment Guidelines',
'author': 'National Institutes of Health',
'year': '2024'},
{ 'key': 'e_1_2_11_27_1',
'unstructured': 'FUJIFILM Toyama Chemical Co. L.Notice of the New Drug Application '
'Approval of “AVIGAN® Tablet 200mg” in Japan for the Anti‐influenza Virus '
'Drug.https://www.cdc.gov.tw/File/Get/ht8jUiB_MI‐aKnlwstwzvw'},
{ 'key': 'e_1_2_11_28_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ebiom.2020.103204'},
{'key': 'e_1_2_11_29_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.00819-20'},
{ 'issue': '1',
'key': 'e_1_2_11_30_1',
'doi-asserted-by': 'crossref',
'first-page': '1',
'DOI': '10.1038/s41467-020-18463-z',
'article-title': 'Rapid incorporation of Favipiravir by the fast and permissive viral RNA '
'polymerase complex results in SARS‐CoV‐2 lethal mutagenesis',
'volume': '11',
'author': 'Shannon A',
'year': '2020',
'journal-title': 'Nat Commun'},
{ 'key': 'e_1_2_11_31_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41467-021-21992-w'},
{ 'key': 'e_1_2_11_32_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.antiviral.2020.104786'},
{ 'key': 'e_1_2_11_33_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ebiom.2020.103125'},
{'key': 'e_1_2_11_34_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/bcp.15227'},
{'key': 'e_1_2_11_35_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/psp4.12685'},
{ 'key': 'e_1_2_11_36_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1007/s40495-020-00226-5'},
{'key': 'e_1_2_11_37_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/psp.2012.4'},
{'key': 'e_1_2_11_38_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/psp.2013.14'},
{ 'key': 'e_1_2_11_39_1',
'doi-asserted-by': 'crossref',
'unstructured': 'SirijatuphatR ManosuthiW NiyomnaithamS et\xa0al.Early treatment of '
'Favipiravir in COVID‐19 patients without pneumonia: a multicentre '
'open‐labelled randomized Control Study.medRxiv.2022.',
'DOI': '10.1101/2022.06.06.22275902'},
{ 'key': 'e_1_2_11_40_1',
'first-page': '1',
'volume-title': 'Bioanalytical Method Validation: Guidance for Industry',
'author': 'U.S. Department of Health and Human Services FaDA',
'year': '2018'},
{'key': 'e_1_2_11_41_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1345/aph.1E259'},
{ 'key': 'e_1_2_11_42_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.antiviral.2015.07.003'},
{'key': 'e_1_2_11_43_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1208/s12248-011-9255-z'},
{ 'key': 'e_1_2_11_44_1',
'volume-title': 'R: A Language and Environment for Statistical Computing',
'author': 'R Core Team',
'year': '2020'},
{ 'key': 'e_1_2_11_45_1',
'unstructured': 'BorchersHW.pracma: Practical Numerical Math Functions. R package version '
'2.2.9.https://CRAN.R‐project.org/package=pracma2019.'},
{ 'key': 'e_1_2_11_46_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.mjafi.2020.08.004'},
{ 'key': 'e_1_2_11_47_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1007/s00467-021-05111-x'},
{ 'key': 'e_1_2_11_48_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/s2055-6640(20)30016-9'},
{ 'key': 'e_1_2_11_49_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1371/journal.pntd.0005389'},
{'key': 'e_1_2_11_50_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cpt.1909'},
{'key': 'e_1_2_11_51_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1073/pnas.2014441117'},
{ 'issue': '6',
'key': 'e_1_2_11_52_1',
'doi-asserted-by': 'crossref',
'first-page': '805',
'DOI': '10.3390/antibiotics11060805',
'article-title': 'Real‐world effectiveness and optimal dosage of favipiravir for '
'treatment of COVID‐19: results from a multicenter observational study '
'in Thailand',
'volume': '11',
'author': 'Rattanaumpawan P',
'year': '2022',
'journal-title': 'Antibiotics'},
{ 'key': 'e_1_2_11_53_1',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41525-020-00143-y'}],
'container-title': 'Pharmacology Research & Perspectives',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.1233',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2024, 11, 7]],
'date-time': '2024-11-07T19:50:11Z',
'timestamp': 1731009011000},
'score': 1,
'resource': {'primary': {'URL': 'https://bpspubs.onlinelibrary.wiley.com/doi/10.1002/prp2.1233'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2024, 11, 7]]},
'references-count': 52,
'journal-issue': {'issue': '6', 'published-print': {'date-parts': [[2024, 12]]}},
'alternative-id': ['10.1002/prp2.1233'],
'URL': 'http://dx.doi.org/10.1002/prp2.1233',
'relation': {},
'ISSN': ['2052-1707', '2052-1707'],
'subject': [],
'container-title-short': 'Pharmacology Res & Perspec',
'published': {'date-parts': [[2024, 11, 7]]},
'assertion': [ { 'value': '2024-03-25',
'order': 0,
'name': 'received',
'label': 'Received',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2024-06-11',
'order': 2,
'name': 'accepted',
'label': 'Accepted',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2024-11-07',
'order': 3,
'name': 'published',
'label': 'Published',
'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
